Intuitive Surgical’s Growth Trajectory Remains Uninterrupted

The leader in robotic-assisted surgery, Intuitive Surgical, continues to demonstrate robust expansion. Recent financial results confirm that demand for its precision medical technology persists, even within a challenging economic climate, supported by consistent double-digit growth in procedure volumes and an expanding global installed base of its systems.

A key driver of the company's momentum is the sustained increase in surgical procedures utilizing its platforms. In the fourth quarter of 2025, Intuitive Surgical reported revenue of approximately $2.87 billion, marking a 19% year-over-year increase. This performance was fueled by significant procedure growth across its product lines.

Procedures conducted with the established da Vinci surgical system grew by roughly 18%. Meanwhile, the company's newer Ion platform, designed for minimally invasive lung biopsies, saw a remarkable 51% surge in procedures. This highlights the successful adoption and expansion of Intuitive's broader ecosystem beyond its flagship offering.

Expanding the Global Installed Base

Parallel to the procedure growth, Intuitive Surgical aggressively placed new systems worldwide. The company installed 532 new da Vinci systems in the final quarter of 2025 alone. By the end of that year, the global installed base reached 11,106 systems, representing a 12% increase from the prior year. Each new installation represents a potential long-term revenue stream, reinforcing the company's market penetration strategy.

The Power of a Recurring Revenue Model

A cornerstone of Intuitive Surgical's financial stability is its heavy reliance on recurring revenue streams. Approximately 75% of total revenue is generated from services, instruments, and accessories. Notably, revenue from consumables alone constitutes about 60% of total sales.

Should investors sell immediately? Or is it worth buying Intuitive Surgical?

This business model ensures that every installed system produces continuous cash flow over its operational lifetime. Strategically, the company is increasingly targeting ambulatory surgery centers. To efficiently penetrate this segment, Intuitive is also leveraging refurbished older system models.

Despite these operational strengths, the market's valuation has shown recent pressure. Shares closed at $504.22 on Friday, reflecting a year-to-date decline of approximately 10.28%. The 14-day Relative Strength Index (RSI) stood at 73.5.

Strategic Outlook for 2026

Management's guidance for the current fiscal year anticipates da Vinci procedure growth in the range of 13% to 15%. A primary catalyst is expected to be the new da Vinci 5 system, which recently received FDA clearance for minimally invasive cardiac surgery. Early feedback from the U.S. market suggests higher utilization rates for these new systems.

The strategic focus for 2026 will be the global scaling of this new equipment generation and deeper penetration into the outpatient surgery market. With a forecast for double-digit procedure growth, the company's operational roadmap for the coming months remains clearly defined.

Key Data Summary

• Q4 2025 Revenue: ~$2.87 billion (+19%)
• 2025 da Vinci Procedure Growth: ~18%
• 2025 Ion Procedure Growth: ~51%
• Total Installed Base (Dec 31, 2025): 11,106 systems
• Recurring Revenue Share: ~75%